Influence of acotiamide on ¹³C-urea breath test for <i>Helicobacter pylori</i> diagnosis

Abstract

The Helicobacter pylori infection and functional dyspepsia are often coexisted. The effect of acotiamide, a drug for functional dyspepsia, on the result of Helicobacter pylori diagnosis has yet to be studied. We evaluated the influence of acotiamide on the results of Helicobacter pylori diagnosis in the 13 C urea breath test. Twenty patients with Helicobacter pylori positive functional dyspepsia were treated with 100 mg of acotiamide three times a day for two weeks. Changes in 13 C urea breath test were investi gated before and after administration, and two weeks after administration as the follow up period. The 13 C urea breath test and the medical questionnaire of modified frequency scale for the symptoms of gastroesophageal reflux disease were conducted at every period. Nineteen patients were included for analysis. No patients showed negative in 13 C urea breath test at Weeks 2 and 4. On the symptom scale, dyspepsia and total scores decreased from Week 0 to Week 2 and increased from Week 2 to Week 4, and the improvement rates of the dyspepsia score at Week 2 was 63%. In conclusion, we confirmed that acotiamide is unlikely to influence the result of 13 C urea breath test and it may improve the symptoms of functional dyspepsia during Helicobacter pylori eradication treatment.

Fibroblasts: Heterogeneous Cells With Potential in Regenerative Therapy for Scarless Wound Healing

“…Skipping treatment has also been suggested. Since chronic inflammation of the reticular dermis is the main cause of pathological scars, treatment strategies can be focused on preventing or dampening inflammation ( Mizukami et al, 2020 ). Inflammatory infiltration in the dermis eventually activates Frs, contributing to altered ECM deposition and finally skin fibrosis.…”

Modern Possibilities of Using Acotiamide in the Treatment of Functional Dyspepsia

“…Поскольку у больных ФД нередко выявляется сопутствующая инфекция Helicobacter pylori (Н. pylori), представляла интерес возможность влияния терапии акотиамидом на результаты тестирования на наличие данной инфекции. Было установлено, что применение акотиамида в дозе 100 мг 3 раза в сутки не влияло на показатели 13 С-уреазного дыхательного теста на Н. pylori [29].…”